Dalpiciclib is a drug for the treatment of various forms of cancer.
In China, dalpiciclib is approved for use in combination with fulvestrant for treatment of HR-positive, HER2-negative recurrent, or metastatic breast cancer in patients who have progressed after previous endocrine therapy.
Dalpicicilib is a CDK inhibitor that targets the CDK4 and CDK6 isoforms.